Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2029
Summary Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism-neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.
Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinson’s market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.
the analyst anticipates that the global PD market will experience significant growth during the forecast period; global sales are expected to increase from $3.5B in 2019 to $11.5B in 2029, at a Compound Annual Growth Rate (CAGR) of 12.6%. This growth will be driven by the launch of 17 late-stage pipeline products. The highest selling drugs are expected to be: Roche/Prothena’s PRX-002 followed by Novo Nordisk’s Victoza. PRX-002 is a mAb with disease-modifying properties. KOLs were optimistic about this drug and suggested it may revolutionize PD treatment. Also, the MOA of Victoza was highly regarded as a potential neuroprotective drug in addition to its established high safety profile.
Key Highlights - Current treatments for both early and advanced stage patients focus on controlling the level of dopamine in the brain.
- anticipate that 17 late stage pipeline drugs will launch over the forecast period. These will begin address longstanding unmet needs and are expected to be the main driver of growth in the PD market across the 7MM.
- Roche/Prothena’s, a monoclonal antibody, has a novel MOA in the PD market and, if approved, will be revolutionary with potential neuroprotective properties.
- The unmet need for therapies for treating late stage complications, such as wearing off, dyskinesia, and psychosis will remain unmet in the 5EU and Japan.
- Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which have potential disease modifying properties.
Key Questions Answered - What are the key PD treatments in 2019?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?
Scope - Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2019 to 2029.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase IIb and Phase III development are profiled.
- Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Our reports have been used by over 10K customers, including:
The global narcolepsy market is expected to reach US$ 4,537.9 Mn in 2027 from US$ 2,026.8 Mn in 2018. The market is estimated to grow with a CAGR of 9.5% from 2019-2027. The growth of the narcolepsy market is primarily attributed to the rising prevalence of sleep related neurological disorders, emerging local pharmaceutical and biopharmaceutical...
Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline Summary Innovation in developing new products is the key element in growth in the pharmaceutical industry.The market is highly research-intensive, powered by high R&D investment, and it possesses a strong product pipeline...
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2018 Summary Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. The latest report Orexin Receptor Type 1 - Pipeline Review, H2 2018, outlays comprehensive...
Narcolepsy: Opportunity Analysis and Forecasts to 2027 Summary Drug sales for Narcolepsy in 2017 were approximately $1.39B across the seven major markets(US, France, Germany, Italy, Spain, UK, and Japan). Over the 10-year forecast period, the market is expected to grow to $3.7B at a CAGR of 10.4%....
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H1 2018 Summary Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled...
Prescription Drug Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.